Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Contineum Therapeutics (CTNM) EPS (Basic): 2023-2024

Historic EPS (Basic) for Contineum Therapeutics (CTNM) over the last 2 years, with Dec 2024 value amounting to -$0.57.

  • Contineum Therapeutics' EPS (Basic) fell 7.55% to -$0.57 in Q4 2024 from the same period last year, while for Dec 2024 it was -$4.91, marking a year-over-year decrease of 76.62%. This contributed to the annual value of -$2.18 for FY2024, which is 260.29% down from last year.
  • Latest data reveals that Contineum Therapeutics reported EPS (Basic) of -$0.57 as of Q4 2024, which was down 42.50% from -$0.40 recorded in Q3 2024.
  • Contineum Therapeutics' 5-year EPS (Basic) high stood at $2.56 for Q2 2023, and its period low was -$3.55 during Q1 2024.
  • Its 2-year average for EPS (Basic) is -$0.96, with a median of -$0.55 in 2023.
  • Data for Contineum Therapeutics' EPS (Basic) shows a peak YoY increase of 85.13% (in 2024) and a maximum YoY decrease of 115.23% (in 2024) over the last 5 years.
  • Over the past 2 years, Contineum Therapeutics' EPS (Basic) (Quarterly) stood at -$0.53 in 2023, then dropped by 7.55% to -$0.57 in 2024.
  • Its EPS (Basic) stands at -$0.57 for Q4 2024, versus -$0.40 for Q3 2024 and -$0.39 for Q2 2024.